| Name | Olanzapine |
| Description | Olanzapine (LY170053) is an atypical antipsychotic that is used currently in the treatment of schizophrenia and bipolar illness. |
| In vitro | Olanzapine is a potent antagonist of DA and 5-HT receptors, which elevates the extracellular levels of DA metabolites, such as DOPAC, and the DA metabolite 3-methoxytyramine, in the prefrontal cortex, nucleus accumbens, and striatum of rats. Subcutaneous injections of Olanzapine (0.5-10 mg/kg) increase the levels of dopamine (DA) and norepinephrine (NE) in these regions in a dose-dependent manner. Additionally, Olanzapine significantly inhibits insulin, leading to the onset of obesity. |
| In vivo | Olanzapine interacts with several key receptors associated with schizophrenia, demonstrating nanomolar affinity for dopamine, serotonin, alpha-1 adrenergic, and cholinergic receptors. Specifically, Olanzapine selectively targets striatal dopamine in the limbic and cortical regions of the brain, exhibiting no selectivity towards dopamine receptor subtypes. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 240 mg/mL (768.17 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (16 mM), Sonication is recommended.
|
| Keywords | SH-SY5Y | Serotonin Receptor | Olanzapine | neuronal | Muscarinic acetylcholine receptor | Mitophagy | Mitochondrial Autophagy | mitochondrial | mAChR | LY-170053 | LY 170053 | Inhibitor | inhibit | HT | DopamineReceptor | Dopamine Receptor | Dopamine | damage | cell | Beta Receptor | Autophagy | Apoptosis | antipsychotic | anticholinergic | AdrenergicReceptor | Adrenergic Receptor | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT2 | 5-HT Receptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Formamide | Paeonol | Naringin | N,N-Dicyclohexylcarbodiimide | Alginic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
